Intratumoral Immunotherapies Currently Undergoing Development & Updated on Efficacy Data

Time: 11:00 am
day: Day Two


  • Review of all intratumoral immunotherapies that have been approved or have shared efficacy and safety results from clinical development
  • Challenges for intratumoral immunotherapy development, best endpoint to target
  • Predictive biomarkers; how and when assess them